The latest price target for Acrivon Therapeutics (NASDAQ:ACRV) was reported by BMO Capital on November 14, 2024. The analyst firm set a price target for $27.00 expecting ACRV to rise to within 12 months (a possible 329.25% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Acrivon Therapeutics (NASDAQ:ACRV) was provided by BMO Capital, and Acrivon Therapeutics maintained their outperform rating.

The last upgrade for Acrivon Therapeutics Inc happened on September 16, 2024 when Ladenburg Thalmann raised their price target to $16. Ladenburg Thalmann previously had a neutral for Acrivon Therapeutics Inc.

The last downgrade for Acrivon Therapeutics Inc happened on April 29, 2024 when Ladenburg Thalmann changed their price target from N/A to N/A for Acrivon Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a maintained with a price target of $28.00 to $27.00. The current price Acrivon Therapeutics (ACRV) is trading at is $6.29, which is out of the analyst’s predicted range.